Clinical Trial: Metabolic Status and Risk of Chronic Kidney Disease in French Overseas Populations With Morbid Obesity (OBECAMcohort).

U.S., Sept. 22 -- ClinicalTrials.gov registry received information related to the study (NCT07830030) titled 'Metabolic Status and Risk of Chronic Kidney Disease in French Overseas Populations With Morbid Obesity (OBECAMcohort).' on Sept. 14.

Brief Summary: Morbid obesity is defined by a body mass index (BMI) >= 40 kg/m2 or > 35 if there is at least one comorbidity (hypertension, diabetes, hypercholesterolemia, joint pain, obstructive sleep apnea syndrome, etc.) Morbid obesity significantly increases the prevalence of comorbidities, such as cardiovascular and metabolic diseases, chronic kidney disease (CKD), cancers, etc. .

The main objective is to assess, at 5 years, the incidence (or progression) of CKD, depending on the presence or abs...